Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation

Jie Zhang; Pengxing He; Yong Xi; Meiyu Geng; Yi Chen; Jian Ding

doi:10.18632/oncotarget.27441

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation

PDF | How to cite

Oncotarget. 2020; 11:302-303. https://doi.org/10.18632/oncotarget.27441

Metrics: PDF 1384 views | ?

Jie Zhang¹, Pengxing He², Yong Xi¹, Meiyu Geng¹, Yi Chen¹, Jian Ding¹

¹ Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
² School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China

Published: January 21, 2020

This article has been corrected: Due to errors in image placement, the representative image of comet assay in group HT29 shG9a for Figure 4B was an accidental duplicate of the picture for SW620 shG9a. The corrected Figure 4 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:2917–2927. DOI: https://doi.org/10.18632/oncotarget.2784.

Figure 4: Down-regulation of G9a induces DNA damage in colon cancer. (A) Karyotype analysis showed that down-regulation of G9a induced chromosome instability (scale bar 10 μM). (B) DNA damage as assessed by the comet assay (scale bar 25 μM). (C) The protein expression levels for G9a, ATM, p-Chk1 (Ser 317), p-Chk2 (Thr 68), γH2AX, and GAPDH (loading control) following the stable knockdown of G9a in HT29 and SW620 cells. (D) Representative immunohistochemical staining images of G9a, Ki67, and γH2AX in xenografts derived from HT29 cells that stably silenced G9a expression (scale bar 25 μM). (E) The quantified results by Image Pro Plus based on the immunohistochemical staining in Figure 4D. **P < 0.01.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27441

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation